Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 18, Number 9—September 2012
CME ACTIVITY - Policy Review

Control of Fluoroquinolone Resistance through Successful Regulation, Australia

Allen C. Cheng, John Turnidge, Peter Collignon, David Looke, Mary Barton, and Thomas GottliebComments to Author 
Author affiliations: Monash University, Melbourne, Victoria, Australia (A.C. Cheng); Alfred Hospital, Melbourne (A.C. Cheng); Women’s and Children’s Hospital, Adelaide, South Australia, Australia (J. Turnidge); University of Adelaide, Adelaide (J. Turnidge); The Canberra Hospital, Garran, Canberra, Australia (P. Collignon); Australian National University, Canberra (P. Collignon); Princess Alexandra Hospital, Brisbane, Queensland, Australia (D. Looke); University of Queensland, Brisbane (D. Looke); University of South Australia, Adelaide (M. Barton); Concord Hospital, Sydney, New South Wales, Australia (T. Gottlieb); and University of Sydney, Sydney (T. Gottlieb)

Main Article

Table 2

Quinolone antimicrobial drugs available for use in companion animals in Australia under the authority of the Pharmaceutical Benefits Scheme

Drug (date registered) Indication
Difloxacin (2001) Treatment of infections in dogs caused by difloxacin-sensitive organisms
Enrofloxacin (2004) Treatment of urinary and respiratory tract infections, deep pyodermas, wounds, abscesses, and discharging sinuses in dogs caused by enrofloxacin-susceptible bacteria
Orbifloxacin (1999) Treatment of diseases in dogs and cats caused by orbifloxacin-sensitive bacteria
Ibafloxacin (2007) Treatment of urinary tract, respiratory tract, skin, and soft tissue infections in dogs and cats caused by ibafloxacin-sensitive bacteria

Main Article

Page created: August 17, 2012
Page updated: August 17, 2012
Page reviewed: August 17, 2012
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.